Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome

Tisagenlecleucel (tisa-cel) is a CD19 specific CAR-T cell product approved for the treatment of relapsed/refractory (r/r) DLBCL or B-ALL. We have followed a group of patients diagnosed with childhood B-ALL ( = 5), adult B-ALL ( = 2), and DLBCL ( = 25) who were treated with tisa-cel under non-clinica...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pathology oncology research 2023-04, Vol.29, p.1610914-1610914
Hauptverfasser: Štach, Martin, Pytlík, Robert, Šmilauerová, Kristýna, Rychlá, Jana, Mucha, Martin, Musil, Jan, Koladiya, Abhishek, Nemec, Matěj, Petráčková, Martina, Kaštánková, Iva, Pecherková, Pavla, Šrámková, Lucie, Polgárová, Kamila, Trněný, Marek, Lesný, Petr, Vydra, Jan, Otáhal, Pavel
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Tisagenlecleucel (tisa-cel) is a CD19 specific CAR-T cell product approved for the treatment of relapsed/refractory (r/r) DLBCL or B-ALL. We have followed a group of patients diagnosed with childhood B-ALL ( = 5), adult B-ALL ( = 2), and DLBCL ( = 25) who were treated with tisa-cel under non-clinical trial conditions. The goal was to determine how the intensive pretreatment of patients affects the produced CAR-T cells, their expansion, and the outcome of the therapy. Multiparametric flow cytometry was used to analyze the material used for manufacturing CAR-T cells (apheresis), the CAR-T cell product itself, and blood samples obtained at three timepoints after administration. We present the analysis of memory phenotype of CD4/CD8 CAR-T lymphocytes (CD45RA, CD62L, CD27, CD28) and the expression of inhibitory receptors (PD-1, TIGIT). In addition, we show its relation to the patients' clinical characteristics, such as tumor burden and sensitivity to prior therapies. Patients who responded to therapy had a higher percentage of CD8 CD45RA CD27 T cells in the apheresis, although not in the produced CAR-Ts. Patients with primary refractory aggressive B-cell lymphomas had the poorest outcomes which was characterized by undetectable CAR-T cell expansion . No clear correlation of the outcome with the immunophenotypes of CAR-Ts was observed. Our results suggest that an important parameter predicting therapy efficacy is CAR-Ts' level of expansion but not the immunophenotype. After CAR-T cells' administration, measurements at several timepoints accurately detect their proliferation intensity . The outcome of CAR-T cell therapy largely depends on biological characteristics of the tumors rather than on the immunophenotype of produced CAR-Ts.
ISSN:1532-2807
1219-4956
1532-2807
DOI:10.3389/pore.2023.1610914